Bronchiectasis

Quick Reference

Critical Alerts

• Massive hemoptysis (> 200 mL/24h) is life-threatening: Requires emergent bronchial artery embolization and ICU admission
• Pseudomonas aeruginosa colonization significantly worsens prognosis: Associated with 3-fold increased mortality and accelerated lung function decline [1]
• Always obtain sputum culture during exacerbations: Prior culture results guide empiric antibiotic selection
• 14-day antibiotic courses are standard for exacerbations: Not 5-7 days as in simple respiratory infections
• Non-tuberculous mycobacteria (NTM) must be considered: If failing standard treatment, obtain AFB smear and culture
• Chronic hypercapnia common: Target SpO2 88-92% to avoid suppressing respiratory drive
• Airway clearance is as important as antibiotics: Daily physiotherapy is cornerstone of management
• Screen for underlying causes in all new diagnoses: Immunoglobulin levels, Aspergillus serology, CF genotype in younger patients

Classic Presentation

Emergency Treatments

---

Definition

Overview

Bronchiectasis is a chronic respiratory disease characterized by permanent, abnormal dilation of the bronchi (> 2 mm diameter airways) with destruction of bronchial wall elastic and muscular components, impaired mucociliary clearance, chronic bacterial colonization, and persistent inflammation [1,2]. It is defined radiologically as bronchial dilatation with broncho-arterial ratio > 1.0 (internal airway diameter exceeding adjacent pulmonary artery), lack of normal bronchial tapering, and visibility of airways within 1 cm of pleural surface [3].

Non-cystic fibrosis (non-CF) bronchiectasis represents a heterogeneous syndrome arising from diverse etiologies including post-infectious damage, immunodeficiency states, allergic bronchopulmonary aspergillosis (ABPA), autoimmune conditions, and chronic aspiration. Unlike cystic fibrosis, which results from a specific genetic defect in the CFTR chloride channel, non-CF bronchiectasis represents the end-stage pathological consequence of various insults to airway structure and function [4].

The hallmark clinical features are chronic productive cough with daily sputum production, recurrent respiratory infections requiring multiple antibiotic courses annually, and progressive decline in lung function. The disease follows a characteristic "vicious cycle" of infection, inflammation, impaired clearance, and structural damage, which perpetuates itself even after the initial insult has resolved [5].

Classification

Morphological Classification (Reid Classification) [6]:

By Etiology [7]:

By Severity - Bronchiectasis Severity Index (BSI) [8]:

BSI Score Interpretation:

• Mild (0-4): 4-year mortality 5-8%
• Moderate (5-8): 4-year mortality 12-16%
• Severe (≥9): 4-year mortality 27-35%

Epidemiology

Prevalence and Incidence [9,10]:

• Overall prevalence (UK): 566 per 100,000 population; increasing significantly with age
• Age > 75 years: Prevalence exceeds 1,000 per 100,000
• Incidence (UK): 21-30 per 100,000 person-years, increasing year-on-year
• Global variation: Higher in low-to-middle income countries with high burden of childhood respiratory infections and tuberculosis
• Trend: Rising prevalence attributed to improved survival, increased use of CT imaging, and aging population

Demographics:

• Age: Bimodal distribution - peak in young adults (primary ciliary dyskinesia, CF) and elderly (post-infectious, COPD overlap)
• Sex: Female predominance in non-CF bronchiectasis (1.5-2:1 female:male ratio) [11]
  • "Lady Windermere syndrome": Middle lobe/lingular bronchiectasis with NTM in elderly thin women
  • "Exception: Post-TB bronchiectasis more common in males"
• Ethnicity: Higher rates in Indigenous populations (Australia, New Zealand, Alaska), likely related to childhood infection burden

Comorbidity Burden [12]:

---

Pathophysiology

Cole's Vicious Cycle Hypothesis [5,13]

The pathogenesis of bronchiectasis is conceptualized as a self-perpetuating "vicious cycle" of four interconnected processes:

              INITIAL INSULT
     (Infection, Obstruction, Immune Defect)
                     |
                     v
    +---> IMPAIRED MUCOCILIARY CLEARANCE < --+
    |                |                       |
    |                v                       |
    |        BACTERIAL COLONIZATION          |
    |     (Biofilm formation, persistence)   |
    |                |                       |
    |                v                       |
    |        CHRONIC INFLAMMATION            |
    |   (Neutrophils, proteases, cytokines)  |
    |                |                       |
    |                v                       |
    +---- STRUCTURAL AIRWAY DAMAGE ----------+
         (Bronchial wall destruction,
          dilation, loss of elasticity)

Stage 1: Initial Insult

• Childhood respiratory infection (pneumonia, pertussis, measles, TB)
• Congenital defects (CF, primary ciliary dyskinesia)
• Immune deficiency (hypogammaglobulinemia)
• Allergic inflammation (ABPA)
• Mechanical obstruction (foreign body, tumor)

Stage 2: Impaired Mucociliary Clearance

• Normal mucociliary escalator clears 1-2 L mucus daily
• Damage to ciliated epithelium reduces clearance velocity
• Mucus stasis creates favorable environment for bacterial growth
• Goblet cell hyperplasia produces excessive, viscid mucus

Stage 3: Bacterial Colonization and Biofilm Formation [14]

• Bacteria colonize stagnant mucus
• Biofilm formation creates protected bacterial communities
• Biofilms are 100-1000x more resistant to antibiotics
• Chronic colonization triggers persistent inflammation
• Pseudomonas aeruginosa particularly forms robust biofilms

Stage 4: Chronic Neutrophilic Inflammation

• Neutrophil influx is the dominant inflammatory response
• Neutrophil elastase, proteinases, and reactive oxygen species released
• Digestion of bronchial wall elastin and collagen
• Pro-inflammatory cytokines (IL-1, IL-6, IL-8, TNF-α) amplify response
• Antiprotease defenses overwhelmed (α1-antitrypsin, SLPI)

Stage 5: Structural Airway Damage

• Destruction of elastic tissue and smooth muscle
• Irreversible bronchial dilation
• Further impairment of mucociliary clearance
• Cycle perpetuates even if initial insult removed

Pathological Features

Macroscopic Findings:

• Dilated bronchi extending to lung periphery
• Bronchial wall thickening (may exceed 2 mm)
• Mucous plugging and purulent secretions
• Peribronchial fibrosis
• Adjacent lung atelectasis or consolidation

Microscopic Findings [15]:

Microbiology [16,17]

Common Colonizing Organisms:

Pseudomonas aeruginosa - Special Considerations [18]:

• Mucoid phenotype develops through alginate biofilm production
• Quorum sensing enables coordinated virulence
• Associated with:
  • More frequent exacerbations (2.5 vs 1.5/year)
  • Accelerated FEV1 decline (60 mL/year vs 30 mL/year)
  • Worse quality of life
  • 3-fold increased mortality at 3 years
  • Greater healthcare utilization

Non-Tuberculous Mycobacteria (NTM) [19]:

Bronchial Arterial Hypertrophy and Hemoptysis [20]

• Chronic inflammation induces bronchial artery hypertrophy and proliferation
• Bronchial arteries normally supply less than 5% of pulmonary blood flow
• In bronchiectasis, may hypertrophy to 3-4 mm diameter (normal less than 1.5 mm)
• Systemic pressure in fragile, inflamed vessels
• Source of hemoptysis in > 90% of cases (not pulmonary arteries)
• Bronchial artery embolization targets these vessels

---

Clinical Presentation

Symptoms

Cardinal Symptoms of Bronchiectasis:

Sputum Characteristics [21]:

• Color: Green/yellow (neutrophilic inflammation); brown (old blood); rust (fresh blood)
• Consistency: Thick, tenacious, difficult to expectorate
• Volume: Increases during exacerbations (may double or triple)
• Odor: Fetid odor suggests anaerobic infection

Exacerbation Definition [1,7]

Acute Exacerbation of Bronchiectasis: Deterioration in THREE or more of the following for at least 48 hours:

• Increased cough frequency
• Increased sputum volume
• Increased sputum purulence (color change)
• Increased dyspnea (breathlessness)
• Increased fatigue/malaise
• Hemoptysis (new or increased)
• Fever (temperature > 38°C)

Exacerbation Frequency Categories:

• Infrequent exacerbator: 0-2 exacerbations/year
• Frequent exacerbator: ≥3 exacerbations/year (associated with worse outcomes)

Physical Examination

General Inspection:

Respiratory Examination:

Cardiovascular Examination:

Red Flags (Life-Threatening Presentations)

Massive Hemoptysis Management Protocol

IMMEDIATE ACTIONS (First 10 minutes):
1. Call for senior help + ICU + Interventional Radiology
2. Position patient with bleeding lung DOWN (if known)
3. High-flow oxygen (unless CO2 retainer)
4. Two large-bore IV cannulas
5. Bloods: FBC, clotting, G&S, crossmatch 6 units
6. IV Tranexamic acid 1g over 10 minutes
7. Nebulized adrenaline 1:1000 (1 mg in 5 mL) may reduce bleeding

STABILIZATION:
- Correct coagulopathy (FFP, vitamin K, platelet transfusion)
- CXR to lateralize bleeding (often unhelpful)
- CT angiography if stable (identifies bronchial artery anatomy)
- Prepare for emergency bronchoscopy

DEFINITIVE TREATMENT:
- Bronchial artery embolization (first-line, 90% success)
- Rigid bronchoscopy for airway control if massive
- Surgery (lobectomy/pneumonectomy) if embolization fails

---

Differential Diagnosis

Conditions Presenting with Chronic Productive Cough

Causes of Hemoptysis

---

Diagnostic Approach

Clinical Assessment

Key History Elements:

1. Symptom characterization: Cough duration, sputum volume/color, hemoptysis, dyspnea
2. Exacerbation frequency: Number per year, triggers, hospitalization history
3. Childhood infections: Severe pneumonia, whooping cough, measles, TB
4. Immune function: Recurrent sinusitis, skin infections, unusual infections
5. Allergic history: Asthma, atopy, ABPA
6. Autoimmune conditions: RA, Sjogren's, IBD
7. GI symptoms: Reflux, dysphagia (aspiration risk)
8. Family history: CF, PCD, immunodeficiency
9. Smoking status: COPD overlap
10. Prior cultures: Known colonizers, sensitivities

Laboratory Investigations

Baseline Tests for All Patients:

Etiological Workup [7,22]:

ABPA Diagnostic Criteria [23]:

1. Asthma or cystic fibrosis
2. Immediate cutaneous reactivity to Aspergillus (skin prick)
3. Total IgE > 1000 IU/mL
4. Elevated Aspergillus-specific IgE/IgG
5. Central bronchiectasis on CT
6. Peripheral blood eosinophilia (> 500/μL)
7. Aspergillus precipitins positive

Imaging

Chest X-ray:

• May be normal in mild disease
• Tram-track sign: Parallel linear opacities (thickened bronchial walls seen longitudinally)
• Ring shadows: Dilated bronchi seen en face
• Tubular opacities: Mucoid impaction
• Air-fluid levels in dilated airways
• Volume loss in affected lobes

High-Resolution CT (HRCT) - Gold Standard [3,24]:

CT Distribution Patterns by Etiology:

Pulmonary Function Tests [25]

Spirometry:

• Obstructive pattern typical (FEV1/FVC less than 0.7)
• Mixed obstructive-restrictive in advanced disease
• FEV1 decline: 50-60 mL/year (accelerated with Pseudomonas)

Additional Tests:

• Static lung volumes: Increased RV/TLC ratio (air trapping)
• Gas transfer (DLCO): Usually preserved (differentiates from emphysema)
• 6-minute walk test: Functional capacity assessment

Bronchoscopy

Indications:

• Localized bronchiectasis (exclude obstruction)
• Hemoptysis localization
• Microbiological sampling when sputum unavailable
• Suspected foreign body
• Therapeutic mucus clearance

---

Treatment

Principles of Management

Bronchiectasis management follows a multimodal approach [1,7]:

1. Treat underlying cause (if identified and treatable)
2. Airway clearance techniques (cornerstone of daily management)
3. Control chronic infection (suppress colonization, treat exacerbations)
4. Reduce inflammation (macrolides for anti-inflammatory effect)
5. Treat exacerbations promptly (14-day antibiotic courses)
6. Manage hemoptysis (tranexamic acid, embolization)
7. Surgery (selected localized disease or massive hemoptysis)
8. Optimize general health (nutrition, vaccination, pulmonary rehabilitation)

---

Airway Clearance Techniques [26,27]

Cornerstone of Management: Daily airway clearance is as important as antibiotics and reduces exacerbation frequency.

Manual Techniques:

Device-Assisted Techniques:

Mucoactive Agents:

Practical Airway Clearance Regimen:

1. Bronchodilator (if prescribed) - 15 minutes prior
2. Nebulized hypertonic saline (if tolerated)
3. Airway clearance technique (ACBT, oscillating PEP)
4. Huff and cough to expectorate
5. Repeat 2-3 times daily (increase during exacerbations)

---

Long-Term Antibiotic Therapy

Indications for Long-Term Macrolide Therapy [28,29]:

• ≥3 exacerbations per year
• Exacerbations requiring hospitalization
• Significant impact on quality of life despite optimized treatment
• Pseudomonas colonization (consider nebulized anti-Pseudomonal as alternative)

Macrolide Regimen:

Evidence (EMBRACE, BAT, BLESS trials) [30]:

• 35-50% reduction in exacerbation frequency
• Improvement in quality of life
• Anti-inflammatory effect (not just antimicrobial)
• Reduces neutrophilic inflammation

Essential Pre-Treatment Workup:

1. ECG: Exclude prolonged QTc (> 450 ms) - macrolides prolong QT
2. Sputum for AFB: Exclude NTM (macrolide monotherapy promotes resistance)
3. Hearing assessment: Ototoxicity risk (especially with aminoglycosides)
4. LFTs: Hepatotoxicity monitoring

Monitoring on Long-Term Macrolides:

• Sputum culture every 6-12 months (monitor for macrolide-resistant organisms)
• Annual audiometry
• Annual ECG
• LFTs if symptomatic

Nebulized Antibiotic Therapy (Pseudomonas-colonized patients) [31]:

Eradication Therapy for New Pseudomonas Isolation [1]:

• Attempt eradication at first isolation
• Two weeks IV anti-Pseudomonal antibiotics (e.g., ceftazidime + tobramycin) OR
• Oral ciprofloxacin 750 mg BD for 2-4 weeks PLUS nebulized colistin for 3 months
• Success rate: 50-80% if attempted early

---

Exacerbation Management [7,32]

Antibiotic Selection:

Key Principles:

• 14 days is standard (not 5-7 days as in simple infections)
• Use prior culture data to guide empiric therapy
• Obtain sputum culture at start of exacerbation
• Increase airway clearance frequency during exacerbation
• Consider IV therapy if oral treatment failing or severe

Hospital Admission Criteria:

• Hypoxia requiring supplemental oxygen (SpO2 less than 92% on air)
• Respiratory distress (RR > 25, accessory muscle use)
• Hemodynamic instability
• Failure of outpatient oral antibiotics
• Unable to manage at home (frailty, social factors)
• Significant hemoptysis
• Need for IV antibiotics
• Comorbidities complicating management

Discharge Criteria:

• Clinically improving (reduced cough, sputum, dyspnea)
• Oxygen at or near baseline
• Tolerating oral antibiotics
• Airway clearance technique reviewed
• Exacerbation action plan in place
• Follow-up arranged (2-4 weeks)

---

Hemoptysis Management [20,33]

Classification:

Medical Management:

Bronchial Artery Embolization (BAE) [34]:

• First-line definitive treatment for massive hemoptysis
• Performed by interventional radiology
• Identifies and occludes hypertrophied bronchial arteries
• Success rate: 85-95% immediate hemostasis
• Recurrence: 10-30% at 1 year (may need repeat)
• Complications: Chest pain, fever, rarely spinal cord ischemia

Surgical Options:

• Lobectomy or pneumonectomy for localized disease with recurrent massive hemoptysis
• Reserved for failed embolization or localized disease unsuitable for embolization
• High-risk in acute setting; elective surgery preferred if possible

---

Treating Underlying Causes

---

Non-Tuberculous Mycobacteria (NTM) Treatment [19,35]

Diagnosis Criteria (ATS/IDSA):

1. Pulmonary symptoms + nodular/cavitary opacities on CT OR bronchiectasis with tree-in-bud
2. Positive culture from: 2+ sputum samples OR 1 bronchoscopy sample OR lung biopsy
3. Exclusion of other diagnoses

MAC (M. avium complex) Treatment:

M. abscessus Treatment:

• Requires IV therapy initially (amikacin + imipenem or cefoxitin)
• Add oral macrolide (if susceptible)
• Treatment duration: 12+ months after culture conversion
• Often incurable; suppressive therapy may be needed

---

Surgical Management [36]

Indications:

• Localized bronchiectasis with failed medical management
• Recurrent massive hemoptysis despite embolization
• Resectable NTM disease not responding to medical therapy
• Localized disease causing significant morbidity
• Pre-transplant volume reduction

Procedures:

Surgical Outcomes:

• Complete symptom resolution: 50-80% in selected patients
• Complications: 10-25% (air leak, empyema, respiratory failure)
• Mortality: 1-5% (higher in bilateral disease)

---

Supportive Care

Vaccination [37]:

Pulmonary Rehabilitation:

• Improves exercise capacity and quality of life
• Reduces dyspnea and fatigue
• May reduce exacerbations
• All symptomatic patients should be offered

Nutritional Support:

• BMI less than 18.5 associated with worse outcomes
• Dietitian referral for malnourished patients
• Oral supplements if inadequate intake
• Treat GERD to reduce aspiration

Psychological Support:

• Anxiety and depression common (30-55%)
• Screen with validated tools (PHQ-9, GAD-7)
• Refer for psychological support if indicated
• Patient support groups

---

Complications

Respiratory Complications

Systemic Complications

---

Prognosis

Mortality and Survival [8,38]

Overall Prognosis:

• 5-year mortality: 10-20% (depending on severity)
• Annual mortality rate: 2-5%
• Main causes of death: Respiratory failure, pneumonia, cardiovascular disease

Prognostic Factors (Poor Prognosis):

Bronchiectasis Severity Index (BSI) Predicted Mortality [8]:

Lung Function Decline [39]

• Average FEV1 decline: 50-60 mL/year
• Pseudomonas colonization: 75-90 mL/year decline
• Successful Pseudomonas eradication may slow decline
• Long-term macrolides may slow decline

---

Patient Education

Condition Explanation

"Bronchiectasis means your airways have become permanently widened and damaged, usually from past lung infections or other conditions. The damage makes it hard for your lungs to clear mucus naturally, so mucus builds up and becomes infected. This causes the symptoms you experience - daily cough, lots of phlegm, and repeated chest infections."

"While we can't reverse the airway damage, we can manage the condition very effectively to reduce infections, improve your breathing, and maintain your quality of life."

Daily Management

Airway Clearance: "Clearing the mucus from your lungs every day is one of the most important things you can do. Your physiotherapist will teach you breathing exercises and techniques. Do these at least twice daily - more when you have an infection. Using hypertonic saline before your exercises can help loosen the mucus."

Recognizing Exacerbations: "Start your 'rescue' antibiotics if you notice:

• More cough than usual
• More phlegm or change in color (especially to green or yellow)
• Feeling more breathless
• Fever or feeling generally unwell
• Blood in your phlegm (small amounts)"

When to Seek Emergency Care: "Call 999 or go to A&E if:

• You cough up more than a tablespoon of blood
• You're very short of breath even at rest
• You feel confused or drowsy
• Your lips or fingers turn blue"

Prevention

"To stay as healthy as possible:

• Never smoke (and avoid secondhand smoke)
• Get your flu jab every year and pneumonia vaccine
• Take all your preventive medications as prescribed
• Do your airway clearance exercises every day
• Stay active - exercise is good for your lungs
• Eat well - good nutrition helps fight infection
• Report infections early - don't wait for them to get severe"

---

Quality Metrics

Performance Indicators

---

Key Clinical Pearls

Diagnostic Pearls

1. HRCT is gold standard: Signet ring sign (bronchus > artery) is pathognomonic
2. Always investigate etiology: Immunoglobulins and Aspergillus serology in all; CF genetics if less than 40 years
3. Sputum culture is essential: Guides antibiotic therapy; obtain at diagnosis and each exacerbation
4. Consider NTM if not responding: Three sputum AFB cultures; common in thin elderly women with middle lobe disease
5. Rule out ABPA: Central bronchiectasis with asthma and elevated IgE suggests ABPA

Treatment Pearls

1. 14-day antibiotic courses for exacerbations: Not 5-7 days
2. Airway clearance is as important as antibiotics: Teach and reinforce at every visit
3. Pseudomonas changes management: Attempt eradication at first isolation; cover in exacerbations
4. Long-term azithromycin for frequent exacerbators: ≥3/year; exclude NTM first with AFB culture
5. Avoid dornase alfa in non-CF bronchiectasis: May worsen outcomes (unlike in CF)

Hemoptysis Pearls

1. Tranexamic acid is first-line for hemoptysis: 500 mg TDS oral or 1g IV
2. Bronchial artery embolization for massive hemoptysis: 85-95% success rate
3. Stop chest physiotherapy during active bleeding: Resume once hemoptysis settles

Red Flag Pearls

1. Massive hemoptysis (> 200 mL/24h): Life-threatening emergency requiring bronchial artery embolization
2. Treatment-resistant exacerbations: Consider NTM, resistant organisms, or non-infectious cause
3. New localized bronchiectasis in adults: Exclude endobronchial obstruction (cancer, foreign body)

---

References

1. Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50(3):1700629. doi:10.1183/13993003.00629-2017

2. Hill AT, Sullivan AL, Chalmers JD, et al. British Thoracic Society Guideline for bronchiectasis in adults. Thorax. 2019;74(Suppl 1):1-69. doi:10.1136/thoraxjnl-2018-212463

3. Defined by HRCT criteria per: Hansell DM, Bankier AA, MacMahon H, et al. Fleischner Society: glossary of terms for thoracic imaging. Radiology. 2008;246(3):697-722. doi:10.1148/radiol.2462070712

4. Flume PA, Chalmers JD, Olivier KN. Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity. Lancet. 2018;392(10150):880-890. doi:10.1016/S0140-6736(18)31767-7

5. Cole PJ. Inflammation: a two-edged sword--the model of bronchiectasis. Eur J Respir Dis Suppl. 1986;147:6-15. doi:10.1186/s12931-019-1014-5

6. Reid LM. Reduction in bronchial subdivision in bronchiectasis. Thorax. 1950;5(3):233-247. doi:10.1136/thx.5.3.233

7. Chalmers JD, Aliberti S, Blasi F. Management of bronchiectasis in adults. Eur Respir J. 2015;45(5):1446-1462. doi:10.1183/09031936.00119114

8. Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med. 2014;189(5):576-585. doi:10.1164/rccm.201309-1575OC

9. Quint JK, Millett ER, Joshi M, et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. Eur Respir J. 2016;47(1):186-193. doi:10.1183/13993003.01033-2015

10. Weycker D, Hansen GL, Seifer FD. Prevalence and incidence of noncystic fibrosis bronchiectasis among US adults in 2013. Chron Respir Dis. 2017;14(4):377-384. doi:10.1177/1479972317709649

11. Lonni S, Chalmers JD, Goeminne PC, et al. Etiology of non-cystic fibrosis bronchiectasis in adults and its correlation to disease severity. Ann Am Thorac Soc. 2015;12(12):1764-1770. doi:10.1513/AnnalsATS.201507-472OC

12. McDonnell MJ, Aliberti S, Goeminne PC, et al. Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study. Lancet Respir Med. 2016;4(12):969-979. doi:10.1016/S2213-2600(16)30320-4

13. King PT. The pathophysiology of bronchiectasis. Int J Chron Obstruct Pulmon Dis. 2009;4:411-419. doi:10.2147/COPD.S6133

14. Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol. 2004;2(2):95-108. doi:10.1038/nrmicro821

15. Whitwell F. A study of the pathology and pathogenesis of bronchiectasis. Thorax. 1952;7(3):213-239. doi:10.1136/thx.7.3.213

16. Finch S, McDonnell MJ, Abo-Leyah H, et al. A comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis. Ann Am Thorac Soc. 2015;12(11):1602-1611. doi:10.1513/AnnalsATS.201506-333OC

17. Loebinger MR, Wells AU, Hansell DM, et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J. 2009;34(4):843-849. doi:10.1183/09031936.00003709

18. Davies G, Wells AU, Doffman S, et al. The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis. Eur Respir J. 2006;28(5):974-979. doi:10.1183/09031936.06.00074605

19. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367-416. doi:10.1164/rccm.200604-571ST

20. Yoon W, Kim JK, Kim YH, et al. Bronchial and nonbronchial systemic artery embolization for life-threatening hemoptysis: a comprehensive review. Radiographics. 2002;22(6):1395-1409. doi:10.1148/rg.226015180

---

Viva Voce Questions

Basic Understanding Questions

Q1: Define bronchiectasis and describe its key pathological features.

• Permanent abnormal dilation of bronchi (> 2mm airways) with destruction of bronchial wall components
• Key features: Loss of elastic tissue, smooth muscle atrophy, cartilage destruction
• Mucociliary dysfunction leading to mucus stasis and chronic infection
• Classifications: Cylindrical (most common), varicose, cystic (most severe)

Q2: Explain Cole's vicious cycle hypothesis.

• Initial insult damages airways (infection, obstruction, immune defect)
• Leads to impaired mucociliary clearance
• Enables bacterial colonization and biofilm formation
• Triggers chronic neutrophilic inflammation with protease release
• Results in structural airway damage, which further impairs clearance
• Cycle becomes self-perpetuating even after initial insult resolved

Q3: What are the HRCT diagnostic criteria for bronchiectasis?

• Signet ring sign: Bronchus diameter exceeds adjacent pulmonary artery (broncho-arterial ratio > 1.0)
• Lack of normal bronchial tapering
• Bronchi visible within 1cm of pleural surface
• Bronchial wall thickening (wall > 50% of diameter)
• Tree-in-bud pattern indicates active small airway infection

Clinical Scenario Questions

Q4: A 65-year-old woman with known bronchiectasis presents with increased cough, green sputum, and fever. Her previous sputum grew Pseudomonas aeruginosa. How would you manage her?

• Recognize as acute exacerbation; meet criteria (≥3 features for ≥48 hours)
• Oral ciprofloxacin 500-750 mg BD for 14 days (covers Pseudomonas based on prior culture)
• If severe or failing oral therapy: IV piperacillin-tazobactam or ceftazidime
• Increase airway clearance frequency
• Send sputum culture to confirm organism and sensitivities
• Discuss admission if hypoxic, septic, or failing oral therapy

Q5: What etiological investigations would you perform in a newly diagnosed bronchiectasis patient?

• All patients: Serum immunoglobulins (IgG, IgA, IgM), total IgE, Aspergillus-specific IgE
• Sputum culture including AFB (rule out NTM)
• Consider: Alpha-1 antitrypsin level, rheumatoid factor
• If age less than 40: Sweat chloride test for cystic fibrosis
• If chronic sinusitis/situs inversus: Nasal nitric oxide for PCD
• If upper lobe disease: Consider previous TB

Q6: A patient with bronchiectasis has had 4 exacerbations in the past year. What long-term management options would you consider?

• First ensure optimized baseline management (airway clearance, vaccinations)
• Long-term azithromycin 250-500mg three times weekly
• Pre-treatment: ECG (exclude prolonged QT), sputum AFB (exclude NTM)
• If Pseudomonas colonized: Consider nebulized antibiotics (colistin, tobramycin)
• Nebulized hypertonic saline to aid secretion clearance
• Pulmonary rehabilitation referral
• Monitor: Sputum culture annually, hearing, LFTs

---

Exam Focus Points

MRCP/FRACP Written Exam

High-Yield Topics:

1. Bronchiectasis Severity Index (BSI) calculation and interpretation
2. Pseudomonas aeruginosa impact on prognosis (3-fold mortality increase)
3. ABPA diagnostic criteria (asthma + elevated IgE + central bronchiectasis)
4. Macrolide prophylaxis indication (≥3 exacerbations/year) and contraindications
5. NTM diagnostic criteria and treatment duration (12 months after culture negative)
6. Dornase alfa is contraindicated in non-CF bronchiectasis

Common Exam Scenarios:

• Identify cause from pattern: Central bronchiectasis = ABPA; Middle lobe in thin elderly woman = NTM
• Manage Pseudomonas colonization: Eradication attempt at first isolation
• Distinguish from COPD: Bronchial dilation on CT, sputum production, recurrent infections

OSCE Stations

History Station Focus:

• Characterize sputum: Volume, color, consistency changes
• Quantify exacerbation frequency: Number per year, hospitalizations
• Screen for causes: Childhood infections, immune problems, reflux, autoimmune
• Functional impact: Exercise tolerance, work, daily activities

Examination Station Focus:

• Look for: Clubbing (30-40%), cachexia, cyanosis
• Auscultate: Coarse crackles (secretions), wheeze (obstruction)
• Cor pulmonale signs: Raised JVP, peripheral edema, loud P2

Management Station Focus:

• Demonstrate airway clearance technique (ACBT, oscillating PEP device)
• Explain exacerbation action plan
• Counsel on long-term antibiotic therapy

---

Version History